ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer

dc.contributor.authorColombo, N.
dc.contributor.authorColeman, R. L.
dc.contributor.authorWu, X.
dc.contributor.authorKose, F.
dc.contributor.authorWenham, R.
dc.contributor.authorSebastianelli, A.
dc.contributor.authorHasegawa, K.
dc.contributor.authorZsiros, E.
dc.contributor.authorRouge, T. De La Motte
dc.contributor.authorBidzinski, M.
dc.contributor.authorMcNeish, I.
dc.contributor.authorSehouli, J.
dc.contributor.authorKorach, J.
dc.contributor.authorDebruyne, P. R.
dc.contributor.authorKim, J-W.
dc.contributor.authorDe Melo, A. C.
dc.contributor.authorPeng, X.
dc.contributor.authorBogusz, A. M.
dc.contributor.authorYamada, K.
dc.contributor.authorMonk, B. J.
dc.date.accessioned2022-12-19T07:25:45Z
dc.date.available2022-12-19T07:25:45Z
dc.date.issued2022
dc.identifier.issn0923-7534en_US
dc.identifier.issueS400en_US
dc.identifier.startpageS401en_US
dc.identifier.urihttps://reader.elsevier.com/reader/sd/pii/S0923753422007475?token=FF8368913AFE07B7B27DE123C04BD2F1633BBD9FEEFA29DFEB4FCD09F08399C552B8F5EFD2205FC9C9DC7CACA5507110&originRegion=eu-west-1&originCreation=20221219072044
dc.identifier.urihttp://hdl.handle.net/11727/8330
dc.identifier.volume33en_US
dc.identifier.wos000814982500045en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.annonc.2022.04.062en_US
dc.relation.journalANNALS OF ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Canceren_US
dc.typeconferenceObjecten_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
96.pdf
Size:
125.2 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: